Trial Profile
A Trial of De-escalation and Stopping Treatment in Chronic Myeloid Leukaemia Patients With Excellent Responses to Tyrosine Kinase Inhibitor Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2022
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DESTINY
- 17 Jun 2022 Results (n=72) of an analysis for modelling of immune response in chronic myeloid leukemia patients presented at the 27th Congress of the European Haematology Association
- 21 Jun 2020 Results performing Predictions and Risk Assessment Using Mathematical Models presented at the 25th Congress of the European Haematology Association
- 14 Feb 2019 This trial has been completed (end date-2018-08-01) in United Kingdom, according to European Clinical Trials Database.